[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100466669":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":37,"locations":43,"responsibleParty":158,"collaborators":160,"id":163,"slug":164,"hasResults":165,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":31,"eligibilityCriteria":169,"healthyVolunteers":165,"sex":170,"minAge":171,"maxAge":31,"enrollmentInfo":172,"targetDuration":31,"studyType":175,"phases":176,"briefSummary":179,"conditions":180,"keywords":31,"overallStatus":46,"whyStopped":31,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},{"fullName":5,"class":6},"Vir Biotechnology, Inc.","INDUSTRY",[8,14,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1 (dose escalation)","EXPERIMENTAL","Participants will receive single-agent VIR-5818",[13],"Drug: VIR-5818",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 2 (dose escalation)","Participants will receive VIR-5818 plus pembrolizumab",[13,18],"Drug: pembrolizumab",{"label":20,"type":10,"description":11,"interventionNames":21},"Part 3 (dose expansion)",[13],{"label":23,"type":10,"description":16,"interventionNames":24},"Part 4 (dose expansion",[13,18],[26,32],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","VIR-5818","Administered as IV infusion",[9,15,20,23],null,{"type":27,"name":33,"description":29,"armGroupLabels":34,"otherNames":35},"pembrolizumab",[15,23],[36],"KEYTRUDA®",[38],{"name":39,"role":40,"phone":41,"phoneExt":31,"email":42},"Study Inquiry","CONTACT","415-654-5281","clinicaltrials@vir.bio",[44,58,71,80,91,102,113,122,128,134,140,149],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":31},"City of Hope National Medical Center","RECRUITING","Duarte","California","91010","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-117.97729,34.13945,{"lat":56,"lon":55},{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":70,"contacts":31},"Investigational site number #100","ACTIVE_NOT_RECRUITING","Melbourne","Victoria","3000","Australia","AU",{"type":53,"coordinates":67},[68,69],144.96332,-37.814,{"lat":69,"lon":68},{"facility":72,"status":46,"city":73,"state":31,"zip":74,"country":64,"countryCode":65,"cosmosGeoPoint":75,"geoPoint":79,"contacts":31},"Investigational site number #101","Randwick","2031",{"type":53,"coordinates":76},[77,78],151.24895,-33.91439,{"lat":78,"lon":77},{"facility":81,"status":46,"city":82,"state":31,"zip":83,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":90,"contacts":31},"Investigational site number #150","Toulouse","31059","France","FR",{"type":53,"coordinates":87},[88,89],1.44367,43.60426,{"lat":89,"lon":88},{"facility":92,"status":46,"city":93,"state":31,"zip":94,"country":95,"countryCode":96,"cosmosGeoPoint":97,"geoPoint":101,"contacts":31},"Investigational site number #200","Porto","4200-072","Portugal","PT",{"type":53,"coordinates":98},[99,100],-8.61097,41.1485,{"lat":100,"lon":99},{"facility":103,"status":46,"city":104,"state":104,"zip":105,"country":106,"countryCode":107,"cosmosGeoPoint":108,"geoPoint":112,"contacts":31},"Investigational site number #257","Madrid","28034","Spain","ES",{"type":53,"coordinates":109},[110,111],-3.70256,40.4165,{"lat":111,"lon":110},{"facility":114,"status":46,"city":115,"state":31,"zip":116,"country":106,"countryCode":107,"cosmosGeoPoint":117,"geoPoint":121,"contacts":31},"Investigational site number #255","Barcelona","08023",{"type":53,"coordinates":118},[119,120],2.15899,41.38879,{"lat":120,"lon":119},{"facility":123,"status":46,"city":115,"state":31,"zip":124,"country":106,"countryCode":107,"cosmosGeoPoint":125,"geoPoint":127,"contacts":31},"Investigational site number #251","08035",{"type":53,"coordinates":126},[119,120],{"lat":120,"lon":119},{"facility":129,"status":46,"city":104,"state":31,"zip":130,"country":106,"countryCode":107,"cosmosGeoPoint":131,"geoPoint":133,"contacts":31},"Investigational site number #254","28027",{"type":53,"coordinates":132},[110,111],{"lat":111,"lon":110},{"facility":135,"status":46,"city":104,"state":31,"zip":136,"country":106,"countryCode":107,"cosmosGeoPoint":137,"geoPoint":139,"contacts":31},"Investigational site number #252","28050",{"type":53,"coordinates":138},[110,111],{"lat":111,"lon":110},{"facility":141,"status":46,"city":142,"state":31,"zip":143,"country":106,"countryCode":107,"cosmosGeoPoint":144,"geoPoint":148,"contacts":31},"Investigational site number #250","Pamplona","31008",{"type":53,"coordinates":145},[146,147],-1.64323,42.81687,{"lat":147,"lon":146},{"facility":150,"status":46,"city":151,"state":31,"zip":152,"country":106,"countryCode":107,"cosmosGeoPoint":153,"geoPoint":157,"contacts":31},"Investigational site number #253","Pozuelo de Alarcón","28223",{"type":53,"coordinates":154},[155,156],-3.81338,40.43293,{"lat":156,"lon":155},{"type":159,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[161],{"name":162,"class":6},"Merck Sharp & Dohme LLC","100466669","phase-1-to-access-the-safety-and-effects-of-intravenous-administration-of-vir-5818-alone-and-in-combination-with-pembrolizumab-in-adult-participants-with-locally-advanced-or-metastatic-her2-expressing-cancers-100466669",false,"NCT05356741","To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers","A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of VIR-5818 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers","Inclusion criteria:\n\n* Written informed consent by the participant (or legally acceptable representative if applicable)\n* Life expectancy of at least 12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Diseases under study, prior lines of therapy, and human epidermal growth factor receptor 2 (HER2) status, per local tests\n\nExclusion criteria:\n\n* Significant cardiopulmonary disease and recent cardiac events\n* History of major organ autoimmune diseases\n* Acute or chronic infections\n\nThe above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.","ALL","18 Years",{"count":173,"type":174},645,"ESTIMATED","INTERVENTIONAL",[177,178],"PHASE1","PHASE2","This first-in-human (FIH) Phase 1 open-label multicenter dose-escalation and dose-expansion study is designed to evaluate the safety, pharmacokinetics, and preliminary activity of VIR-5818 (Formerly AMX-818) as a single agent and in combination with pembrolizumab in participants with HER2+ tumors across multiple tumor types. The study will be conducted in four parts:\n\n* Part 1 (dose escalation): Single-agent VIR-5818\n* Part 2 (dose escalation): VIR-5818 plus pembrolizumab\n* Part 3 (dose expansion): Single-agent VIR-5818\n* Part 4 (dose expansion): VIR-5818 plus pembrolizumab\n\nThe total length of the study, from screening of the first participant to the end of the study, is expected to be approximately 72 months.",[181],"Locally Advanced or Metastatic HER2-Expressing Cancers","2026-08-17",{"date":184,"type":185},"2026-08-19","ACTUAL",{"date":187,"type":185},"2022-04-13",{"date":189,"type":174},"2028-04",{"name":5,"class":6},12]